In high-grade gliomas with a defined mutation (e.g., BRAF mutation, EGFR mutation), patients receiving targeted therapy (tyrosine kinase inhibitor) had a higher overall survival (OS) rate compared to those receiving conventional chemotherapy [50]. Here, EGFR is linked to central nervous system cancer.